PAhR Therapeutics

Drug Discovery · Boston, MA · Founded 2025 · Privately Held (backing)

Operator of a clinical-stage biotechnology company intended to develop novel therapies for pulmonary arterial hypertension through innovative molecular mechanisms. PAhR Therapeutics is based in Boston, MA and was founded in 2025. It was valued at $25 million at its seed round in Jul 2025, the last priced event on record. It has raised $14 million across 1 recorded round; the latest was a $14 million seed round in Jul 2025.

PMV mark · valuation
$25.0M
Oct 2026
Priced at
its seed round
Jul 2025
Total raised
$14.0M
Last round
Seed Round
Jul 2025

Who backs PAhR Therapeutics?

3 investors
InvestorType
RA Capital ManagementAsset manager
The University of Tokyo Edge CapitalOther
AN Ventures—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

PAhR Therapeutics investors

3 investors are on record for PAhR Therapeutics, including RA Capital Management, The University of Tokyo Edge Capital and AN Ventures. The seed round in Jul 2025 drew 2 investors.

Free account
More of PAhR Therapeutics with a free account
  • ·Watch PAhR Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 3 firms already write checks for companies like PAhR Therapeutics in drug discovery. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View